Avitas Wealth Management LLC Trims Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Avitas Wealth Management LLC trimmed its stake in AstraZeneca PLC (NASDAQ:AZN) by 39.2% in the 4th quarter, HoldingsChannel reports. The firm owned 29,409 shares of the company’s stock after selling 18,936 shares during the quarter. Avitas Wealth Management LLC’s holdings in AstraZeneca were worth $1,927,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. McClarren Financial Advisors Inc. lifted its holdings in AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after buying an additional 247 shares during the period. Capital Performance Advisors LLP bought a new position in shares of AstraZeneca in the 3rd quarter worth approximately $28,000. Ashton Thomas Securities LLC purchased a new position in shares of AstraZeneca in the 3rd quarter valued at approximately $45,000. Albion Financial Group UT grew its stake in AstraZeneca by 68.9% in the fourth quarter. Albion Financial Group UT now owns 608 shares of the company’s stock worth $40,000 after purchasing an additional 248 shares during the period. Finally, Hollencrest Capital Management raised its holdings in AstraZeneca by 38.4% in the third quarter. Hollencrest Capital Management now owns 692 shares of the company’s stock worth $54,000 after purchasing an additional 192 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on AZN. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Stock Performance

Shares of AstraZeneca stock opened at $68.96 on Wednesday. The stock has a market cap of $213.85 billion, a price-to-earnings ratio of 33.00, a PEG ratio of 1.18 and a beta of 0.46. The firm’s 50-day moving average is $67.15 and its 200 day moving average is $73.79. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business’s revenue was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.87 earnings per share. Sell-side analysts anticipate that AstraZeneca PLC will post 4.13 EPS for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.